- Home
- APH vs NVO Comparison
APH vs NVO Comparison
Compare APH & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APH | NVO |
|---|---|---|
| Founded | 1932 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.0B | 218.9B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | APH | NVO |
|---|---|---|
| Price | $150.72 | $49.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 11 |
| Target Price | ★ $154.00 | $51.00 |
| AVG Volume (30 Days) | 7.5M | ★ 9.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | 0.67% | ★ 3.19% |
| EPS Growth | ★ 73.96 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.60 | N/A |
| Revenue Next Year | $12.19 | $3.70 |
| P/E Ratio | $209.53 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $95.19 | $35.12 |
| 52 Week High | $178.52 | $71.80 |
Technical Indicators
Market Signals| Indicator | APH | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 59.26 |
| Support Level | $123.24 | $43.14 |
| Resistance Level | $154.81 | $50.45 |
| Average True Range (ATR) | 6.34 | 1.02 |
| MACD | -2.31 | -0.01 |
| Stochastic Oscillator | 14.66 | 48.85 |
Price Performance
Historical ComparisonAbout APH Amphenol Corporation
Amphenol is a global supplier of connectors, sensors, and interconnect systems. It holds the second-largest connector market share globally and sells into the automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks end markets. Amphenol is diversified geographically, with operations in 40 countries.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.